These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35626196)

  • 41. Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: a PRISMA-compliant systematic review and meta-analysis.
    Zhang L; Wu B; Zha Z; Zhao H; Yuan J; Jiang Y
    World J Urol; 2020 Jan; 38(1):129-142. PubMed ID: 30919100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment.
    Fan B; Mohammed A; Huang Y; Luo H; Zhang H; Tao S; Xu W; Liu Q; He T; Jin H; Sun M; Sun M; Yun Z; Zhao R; Wu G; Li X
    Front Oncol; 2021; 11():633462. PubMed ID: 34350107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of Urine Exosomal mRNAs and lncRNAs as Novel Diagnostic Biomarkers for Bladder Cancer.
    Huang H; Du J; Jin B; Pang L; Duan N; Huang C; Hou J; Yu W; Hao H; Li H
    Front Oncol; 2021; 11():667212. PubMed ID: 33987102
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comprehensive analysis of Transcription Factors identified novel prognostic biomarker in human bladder cancer.
    Liao Y; Zou X; Wang K; Wang Y; Wang M; Guo T; Zhong B; Jiang N
    J Cancer; 2021; 12(18):5605-5621. PubMed ID: 34405021
    [No Abstract]   [Full Text] [Related]  

  • 45. Outcomes of palliative cystectomy in patients with locally advanced pT4 bladder cancer.
    Maisch P; Lunger L; Düwel C; Schmid SC; Horn T; Gschwend JE; Sauter A; Heck MM
    Urol Oncol; 2021 Jun; 39(6):368.e11-368.e17. PubMed ID: 33431328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trends in the risk of second primary cancer among bladder cancer survivors: a population-based cohort of 10 047 patients.
    Muller J; Grosclaude P; Lapôtre-Ledoux B; Woronoff AS; Guizard AV; Bara S; Colonna M; Troussard X; Bouvier V; Trétarre B; Velten M; Jégu J
    BJU Int; 2016 Jul; 118(1):53-9. PubMed ID: 26469096
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination of Total Psoas Index and Albumin-Globulin Score for the Prognosis Prediction of Bladder Cancer Patients After Radical Cystectomy: A Population-Based Study.
    Wang K; Gu Y; Ni J; Zhang H; Xie J; Xu T; Geng J; Mao W; Peng B
    Front Oncol; 2021; 11():724536. PubMed ID: 34616677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radiomics analysis of multiparametric MRI for the preoperative evaluation of pathological grade in bladder cancer tumors.
    Wang H; Hu D; Yao H; Chen M; Li S; Chen H; Luo J; Feng Y; Guo Y
    Eur Radiol; 2019 Nov; 29(11):6182-6190. PubMed ID: 31016445
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of bladder cancer in male Japanese workers exposed to ortho-toluidine and other aromatic amines.
    Nakano M; Shinagawa T; Eitaki Y; Omae K; Takeuchi A; Iwasawa S; Fukai K; Yoshioka N; Tanaka S; Koda S; Sobue T; Takebayashi T
    Int Arch Occup Environ Health; 2021 Aug; 94(6):1427-1439. PubMed ID: 33651159
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA methylation patterns of SOCS1 gene in peripheral blood identifies risk loci associated with bladder cancer based on principal component analysis.
    Guan H; Lu J; Qu M; Meng L; Guo Y; Li X; Shen H
    Neoplasma; 2021 May; 68(3):482-489. PubMed ID: 33440990
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Urinary metabolomic signature of muscle-invasive bladder cancer: A multiplatform approach.
    Jacyna J; Wawrzyniak R; Balayssac S; Gilard V; Malet-Martino M; Sawicka A; Kordalewska M; Nowicki Ł; Kurek E; Bulska E; Patejko M; Markuszewski M; Gutknecht P; Matuszewski M; Siebert J; Kaliszan R; Markuszewski MJ
    Talanta; 2019 Sep; 202():572-579. PubMed ID: 31171223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.
    Shen C; Sun Z; Chen D; Su X; Jiang J; Li G; Lin B; Yan J
    OMICS; 2015 Jan; 19(1):1-11. PubMed ID: 25562196
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances in Diagnosis and Therapy for Bladder Cancer.
    Hu X; Li G; Wu S
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804953
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concomitant Gleason Score ≥ 7 prostate cancer is an independent prognosticator for poor survival in nonmetastatic bladder cancer patients undergoing radical cystoprostatectomy.
    Thomas C; Giesswein A; Hainz M; Stein R; Rubenwolf P; Roos FC; Neisius A; Nestler S; Hampel C; Jäger W; Wiesner C; Thüroff JW
    Int Urol Nephrol; 2015 Nov; 47(11):1789-96. PubMed ID: 26377495
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differentiating progressive from nonprogressive T1 bladder cancer by gene expression profiling: applying RNA-sequencing analysis on archived specimens.
    Sharron Lin X; Hu L; Sandy K; Correll M; Quackenbush J; Wu CL; Scott McDougal W
    Urol Oncol; 2014 Apr; 32(3):327-36. PubMed ID: 24055427
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of Urinalysis-Based Screening for Urothelial Carcinoma in Patients With Lynch Syndrome.
    Chouhan H; Abbass MA; Hrabe JE; Ferrandon S; DeVecchio J; Mankaney G; Burke CA; Heald B; Ann LaGuardia L; O'Malley M; Milicia S; Liska D; Church J; Campbell SC; Kalady MF
    Dis Colon Rectum; 2022 Jan; 65(1):40-45. PubMed ID: 34882627
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.
    Tripathi P; Somashekar BS; Ponnusamy M; Gursky A; Dailey S; Kunju P; Lee CT; Chinnaiyan AM; Rajendiran TM; Ramamoorthy A
    J Proteome Res; 2013 Jul; 12(7):3519-28. PubMed ID: 23731241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer.
    Ramirez D; Gupta A; Canter D; Harrow B; Dobbs RW; Kucherov V; Mueller E; Streeper N; Uhlman MA; Svatek RS; Messing EM; Lotan Y
    BJU Int; 2016 May; 117(5):783-6. PubMed ID: 26435378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Health system costs for stage-specific breast cancer: a population-based approach.
    Mittmann N; Porter JM; Rangrej J; Seung SJ; Liu N; Saskin R; Cheung MC; Leighl NB; Hoch JS; Trudeau M; Evans WK; Dainty KN; DeAngelis C; Earle CC
    Curr Oncol; 2014 Dec; 21(6):281-93. PubMed ID: 25489255
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.